i 432

I 432 is a TMPRSS2 (transmembrane serine proteinase 2) inhibitor (Ki =0.9 nM).

UH 301 is a 5-HT1A receptor antagonist.

I-BET432, a BET inhibitor, targets both the N-terminal (BD1) and C-terminal (BD2) bromodomains of BRD4, exhibiting pIC50 values of 7.5 and 7.2, respectively. As an orally administered candidate, I-BET432 holds potential for research in various oncology and inflammatory diseases.

MAGLi 432 is a potent, highly selective, non-covalent, reversible (MAGL) inhibitor that binds with high affinity to the MAGL active site, with IC50 values of 4.2 nM (human enzyme) and 3.1 nM (mouse enzyme), MAGLi 432 can be used to study neurological disorders such as chronic inflammation, multiple sclerosis, blood-brain barrier dysfunction, Alzheimer's disease and Parkinson's disease.

SRI-43265 (compound 40) inhibits the dimerization of human antigen R protein (HuR), which is involved in cancer and inflammation pathogenesis [1].

Tucidinostat (Chidamide) is an effective and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor, with IC50s of 95, 160, 67 and 78 nM, less active on HDAC8/11 (IC50: 733/432 nM), and shows no effect on HDAC4/5/6/7/9.

MEY-003, an Autotaxin (ATX) inhibitor, exhibits EC50 values of 460 nM for hATX-β and 1.09 μM for hATX-ɣ (analysis with LPC18:1), demonstrating its potency against these isoforms. It acts non-competitively with a K i of 432 nM, making it suitable for research into diseases where ATX is implicated [1].

Matriptase-IN-2 free base, a matriptase inhibitor with a K i of 5 nM, has potential applications in musculoskeletal system disorder research (WO2011023958A1; compound 432) [1].